Advertisement

Cardioprotective Effects of Prostacyclin Analogues

  • Fiona M. McDonald
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 177)

Abstract

In recent years, a considerable amount of evidence has accumulated suggesting that prostacyclin and prostacyclin analogues show cardioprotective activity in a number of different models of myocardial injury. Cardioprotective effects may be manifest in a variety of ways, including biochemical (e.g. conservation/improved recovery of mitochondrial oxidative function), morphological (preservation of myocyte ultrastructure), functional (enhancement of local or global mechanical performance) and electrical (anti-arrhythmic) protection. This has resulted in a multitude of parameters being used to assess both the extent of myocardial injury and the degree of myocardial protection. Tables 1 and 2 summarise some of the situations in which effects of prostacyclin or prostacyclin analogues have been seen, and interpreted as cardioprotection.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    K. Schrör and K. Funke, Prostaglandins and myocardial noradrenaline overflow after sympathetic nerve stimulation during ischemia and reperfusion, J. Cardiovasc. Pharmacol. 7 (Suppl. 5): S50 (1985).CrossRefGoogle Scholar
  2. 2.
    R. Ferrati, A. Cargnoni, S. Curello, C. Ceconi and E. Pasini, Protective effects of iloprost during myocardial ischaemia and reperfusion, J. Mol. Cell. Cardiol. 20 (Suppl. V): S41 (1988).Google Scholar
  3. 3.
    W.H. van Gilst, P.W. Boonstra, J.A. Terpstra, C.R.H. Wildevuur and C.D.J. de Langen, Improved recovery of cardiac function after 24 h of hypothermic arrest in the isolated rat heart: comparison of a prostacyclin analogue (ZK 36 374) and a calcium entry blocker (diltiazem), J. Cardiovasc. Pharmacol. 7: 520 (1985).CrossRefGoogle Scholar
  4. 4.
    F. Nomura, H. Matsuda, H. Hirose, S. Nakano, S. Maeda, M. Ohtani, M. Kaneko, K. Kadoba and Y. Kawashima, Assessment of myocardial protective effects of a new prostacyclin analogue, OP-41483, Surg. Forum 37: 265 (1986).Google Scholar
  5. 5.
    E.F. Smith III, G. Kloster, G. Stöcklin and K. Schrör, Effect of iloprost (ZK 36 374) on membrane integrity in ischemic rabbit hearts, Biomed. Biochim. Acta 43: S155 (1984).Google Scholar
  6. 6.
    M. Pissarek, W. Gründer and T. Keller, 31-P-NMR-spectroscopy on ischemic and reperfused rat hearts: effects of iloprost, Biomed. Biochim. Acta 46: S564 (1987).Google Scholar
  7. 7.
    B. Müller, J. Schneider, H.H. Hennies and L. Flohé, Cardioprotective actions of the new stable epoprostenol analogue CG 4203 in rat models of cardiac hypoxia and ischemia, Arzneim.-Forsch./Drug Res. 34: 1506 (1984).Google Scholar
  8. 8.
    H.E. Aksulu, Z.S. Ercan and R.K. Türker, Further studies on the antiarrhythmic effect of iloprost, Arch. Int. Pharmacodyn. Ther. 277: 223 (1985).PubMedGoogle Scholar
  9. 9.
    M. Metin, Ö. Dörtlemez, H. Dörtlemez, F. Akar, Z.S. Erca and R.K. Türker, Prevention by a carbacyclin analogue (ZK 36 374) of digoxin-induced ventricular extrasystoles in guinea-pig myocardium, Eur. J. Pharmcol. 98: 125 (1984).CrossRefGoogle Scholar
  10. 10.
    M. Chiariello, P. Golino, M. Cappelli-Bigazzi, G. Ambrosio, I. Tritto and M. Salvatore, Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion, Am. Heart J. 115: 499 (1988).CrossRefGoogle Scholar
  11. 11.
    P.J. Simpson, S.E. Mitsos, A. Ventura, K.P. Gallagher, J.C. Fantone, G.D. Abrams, M.A. Schork and B.R. Lucchesi, Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophile activation, Am. Heart J. 113: 129 (1987).CrossRefGoogle Scholar
  12. 12.
    P.J. Simpson, J. Mickelson, J.C. Fantone, K.P. Gallagher and B.R. Lucchesi, Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart, Circ. Res. 60: 666 (1987).Google Scholar
  13. 13.
    F.M. Lupinetti, V.A. Starnes, K.A. Laws, J.C. Collins and J.W. Hammon, Prostacyclin reduction of regional ischemic injury in the canine myocardium, J. Surg. Res. 41: 146 (1986).CrossRefGoogle Scholar
  14. 14.
    C.D.J. de Langen, W.H. van Gilst and H. Wessling, Sustained protection by iloprost of the porcine heart in the acute and chronic phases of myocardial infarction, J. Cardiovasc. Pharmacol. 7: 924 (1985).CrossRefGoogle Scholar
  15. 15.
    P.S. Körmöczy, C. Vértesi, E. Mikus, L. Tardos and G. Kovacs, Cardioprotective effect of prostacyclin and 7-oxo-PGI2 in rats against chronic isoproterenol damage, Prostaglandins 3: 505 (1987).CrossRefGoogle Scholar
  16. 16.
    N.E. Farber, G.M. Pieper, J.P. Thomas and G.J. Gross, Beneficial effects of iloprost in the stunned canine myocardium, Circ. Res. 62: 204 (1988).Google Scholar
  17. 17.
    W.J. van der Giessen, B. Schoutsen, J.G.P. Tijssen and P.D. Verdouw, Iloprost (ZK 36374) enhances recovery of regional myocardial function during reperfusion after coronary artery occlusion in the pig, Br. J. Pharmac. 87: 23 (1986).CrossRefGoogle Scholar
  18. 18.
    C. Thiemermann, E. Steinhagen-Thiessen and K. Schrör, Inhibition of oxygen-centered free radical formation by the stable prostacyclin-mimetic iloprost (ZK 36 374) in acute myocardial ischemia, J. Cardiovasc. Pharmacol. 6: 365 (1984).CrossRefGoogle Scholar
  19. 19.
    H. Darius, J.A. Osborne, D.K. Reibel and A.M. Lefer, Protective actions of a stable prostacyclin analog in ischemia induced membrane damage in rat myocardium, J. Mol. Cell. Cardiol. 19: 243 (1987).CrossRefGoogle Scholar
  20. 20.
    H. Darius, T. Thomsen and K. Schrör, Cardiovascular actions in vitro and cardioprotective effects in vivo of nileprost, a mixed type PGI2/PGE2 agonist, J. Cardiovasc. Pharmacol. 10: 144 (1987).CrossRefGoogle Scholar
  21. 21.
    E.F. Smith III, W. Gallenkämper, R. Beckmann, T. Thomsen, G. Mannesmann and K. Schrör, Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size, Cardiovasc. Res. 18: 163 (1984).Google Scholar
  22. 22.
    K. Schrör, H. Darius, R. Ohlendorf, R. Matzky and W. Klaus, Dissociation of antiplatelet effects from myocardial cytoprotective activity during acute myocardial ischemia in cats by a new carbacyclin derivtive (ZK 36 375), J. Cardiovasc. Pharmacol. 4: 554 (1982).PubMedGoogle Scholar
  23. 23.
    K. Schrör, K. Addicks, H. Darius, R. Ohlendorf and P. Rosen, PGI2 inhibits ischemia-induced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator, Thromb. Res. 21: 175 (1981).Google Scholar
  24. 24.
    K. Schrör, R. Ohlendorf and H. Darius, Beneficial effects of a new carbacyclin derivative, ZK 36 374, in acute myocardial ischemia, J. Pharmacol. Exp. Ther. 219: 243 (1981).PubMedGoogle Scholar
  25. 25.
    N. Hieda, Y. Toki, S. Sugiyama, T. Ito, T. Satake and T. Ozawa, Prostaglandin I2 analogue and propranolol prevent ischaemia induced mitochondrial dysfunction through the stabilisation of lysosomal membranes, Cardiovasc. Res. 22: 219 (1988).Google Scholar
  26. 26.
    J.R. Rowles and M.L. Foegh, The synergistic effect of cyclosporine and iloprost on survival of rat cardiac allografts, Transplantation 42: 94 (1986).PubMedGoogle Scholar
  27. 27.
    J.F. Shaw, Prolongation of rat allograft survival by treatment with prostacyclin or aspirin during acute rejection. Transplantation 35: 526 (1983).CrossRefGoogle Scholar
  28. 28.
    W.J. van der Giessen, W.J. Mooi, A.M. Rutteman, L. Berk and P.D. Verdouw, The effects of the stable prostacyclin analogue ZK 36 374 on experimental coronary thrombosis in the pig, Thromb. Res. 36: 45 (1984).Google Scholar
  29. 29.
    W.A. Schumacher, E.C. Lee and B.R. Lucchesi, Augmentation of streptokinase-induced thrombolysis by heparin and prostacyclin, J. Cardiovasc. Pharmacol. 7: 739 (1985).CrossRefGoogle Scholar
  30. 30.
    Y. Uchida and S. Murao, Effects of a prostaglandin I2 analogue, ZK 36374, on recurring reduction of coronary blood flow, Jap. Heart J. 24: 641 (1983).Google Scholar
  31. 31.
    Y. Uchida and S. Murao, Effect of prostaglandin I2 on cyclical reduction of coronary blood flow. Jap. Circ. J. 43: 645 (1979).CrossRefGoogle Scholar
  32. 32.
    B. Müller, B. Maass, S. Stürzebecher and W. Skuballa, Antifibrillatory action of the stable orally active prostacyclin analogues iloprost and ZK 96 480 in rats after coronary artery ligation, Biomed. Biochim. Acta 43: S175 (1984).Google Scholar
  33. 33.
    S.J. Coker and J.R. Parratt, Prostacyclin - antiarrhythmic or arrhythmogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK 36374 during coronary artery occlusion and reperfusion in anaesthetised greyhounds, J. Cardiovasc. Pharmacol. 5: 557 (1983).CrossRefGoogle Scholar
  34. 34.
    M.P. Moffat, Concentration-dependent effects of prostacyclin on the response of the isolated guinea pig heart to ischemia and reperfusion: possible involvement of the slow inward current, J. Pharmacol. Exp. Ther. 242: 292 (1987).PubMedGoogle Scholar
  35. 35.
    M. Karmazyn, Contribution of prostaglandins to reperfusion-induced ventricular failure in isolated rat hearts, Am. J. Physiol. 251: H133 (1986).PubMedGoogle Scholar
  36. 36.
    M.P. Maxwell, D.J. Hearse and D.M. Yellon, Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction, Cardiovasc. Res. 21: 737 (1987).Google Scholar
  37. 37.
    K.M. Mullane and J.C. McGiff, Platelet depletion and infarct size in an occlusion-reperfusion model of myocardial ischemia in anesthetized dogs, J. Cardiovasc. Pharmacol. 7: 733 (1985).CrossRefGoogle Scholar
  38. 38.
    S.R. Jolly, W.A. Schumacher, S.L. Kungel, G.D. Abrams, J. Liddicoat and B.R. Lucchesi, Platelet depletion in experimental myocardial infarction, Basic Res. Cardiol. 80: 269 (1985).Google Scholar
  39. 39.
    V. Kecskemeti, Cardiac electrophysiological effects of prostacyclin analogues, 7-oxo-PGI2 and iloprost. Biomed. Biochim. Acta 46: S460 (1987).PubMedGoogle Scholar
  40. 40.
    R.D. Rossen, J.L. Swain, L.H. Michael, S. Weakley, E. Giannini and M.L. Entman, Selective accumulation of the first component of complement and leucocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury, Circ. Res. 57: 119 (1985).Google Scholar
  41. 41.
    K.M. Mullane, R. Kraemer and B. Smith, Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium, J. Pharmacol. Methods 14: 157 (1985).CrossRefGoogle Scholar
  42. 42.
    G. Feuerstein and J.M. Hallenbeck, Leukotrienes in health and disease, FASEB J. 1: 186 (1987).Google Scholar
  43. 43.
    R. Engler and J.W. Covell, Granulocytes cause reperfusion ventricular dysfunction after 15-minute ischemia in the dog, Circ. Res. 61: 20 (1987).Google Scholar
  44. 44.
    J.L. Romson, B.G. Hook, S.L. Kunkel, G.D. Abrams, A. Schork and B.R. Lucchesi, Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog, Circulation 67: 1016 (1983).CrossRefGoogle Scholar
  45. 45.
    S.R. Jolly, W.J. Kane, B.G. Hook, G.D. Abrams, S.L. Kunkel and B.R. Lucchesi, Reduction of myocardial infarct size by neutro-phil depletion: effect of duration of occlusion, Am. Heart J. 112: 682 (1986).CrossRefGoogle Scholar
  46. 46.
    P.J. Simpson, R.F. Todd III, J.C. Fantone, J.K. Michelson, J.D. Griffin and B.R. Lucchesi, Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (Anti-Mol, Anti-CDllb) that inhibits leukocyte adhesion, J. Clin. Invest. 81: 624 (1988).CrossRefGoogle Scholar
  47. 47.
    G. Ambrosio, L.C. Becker, G.M. Hutchins, H.F. Weisman and M.L. Weisfeldt, Reduction in experimental infarct size by recombinant human superoxide dismutase: insights into the pathophysiology of reperfusion injury, Circulation 74: 1424 (1986).CrossRefGoogle Scholar
  48. 48.
    K. Przyklenk and R.A. Kloner, Superoxide dismutase plus catalase improve contractile function in the canine model of the “stunned myocardium”, Circ. Res. 58: 148 (1986).Google Scholar
  49. 49.
    S.E. Mitsos, J.C. Fantone, K.P. Gallagher, K.M. Walden, P.J. Simpson, G.D. Abrams, M.A. Schork and B.R. Lucchesi, Canine myocardial reperfusion injury: protection by a free radical scavenger, N-2-mercaptopropionyl glycine, J. Cardiovasc. Pharmacol. 8: 978 (1986).CrossRefGoogle Scholar
  50. 50.
    M.L. Myers, R. Bolli, R.F. Lekich, C.J. Harley and R. Roberts, N-2-mercaptopropionylglycine improves recovery of myocardial function after reversible regional ischemia, J. Am. Coll. Cardiol. 8: 1161 (1986).CrossRefGoogle Scholar
  51. 51.
    K.P. Gallagher, A.J. Buda, D. Pace, R.A. Gerren and M Shlafer, Failure of superoxide dismutase and catalase to alter size of infarction in conscious dogs after 3 hours of occlusion followed by reperfusion, Circulation 73: 1065 (1986).CrossRefGoogle Scholar
  52. 52.
    H.J. Stahlberg, G. Loschen and L. Flohé, Effects of prostacyclin analogs on cyclic adenosine monophosphate and superoxide formation in human polymorphonuclear leukocytes stimulated by formyl-methionyl-leucyl-phenylalanine, Biol. Chem. Hoppe-Seyler 369: 329 (1988).CrossRefGoogle Scholar
  53. 53.
    J.J.F. Belch, A. Saniabadi, R. Dickson, R.D. Sturrock and C.D. Forbes, Effect of iloprost (ZK 36374) on white cell behavior, in: “Prostacyclin and Its Stable Analogue Iloprost”, R.J. Gryglewski and G. Stock, eds., Springer Verlag, Berlin, Heidelberg (1987).Google Scholar
  54. 54.
    D. Fricke, D. Damerau and W. Vogt, Adhesion of guinea pig polymorphonuclear leucocytes to autologous aortic strips: influence of chemotactic factors and of pharmacological agents which affect arachidonic acid metabolism, Int. Archs. Allergy appl. Immun. 78: 429 (1985).CrossRefGoogle Scholar
  55. 55.
    B. Miller, M. Schmidtke and W. Witt, Adherence of leucocytes to electrically damaged venules in vivo. Effects of iloprost, PGE, indomethacin, forskolin, BW 755 C, sulotroban, hirudin, andlthrombocytopenia, Eicosanoids 1: 13 (1988).Google Scholar
  56. 56.
    A.L. Willis, D.L. Smith and C. Vigo, Suppression of principal atherosclerotic mechanisms by prostacyclins and other eicosanoids, Prog. Lipid Res. 25: 645 (1986).CrossRefGoogle Scholar
  57. 57.
    A.N. Orekhov, V.V. Tertov, A.V. Mazurov, E.R. Andreeva, V.S. Repin and V.N. Smirnov, “Regression” of atherosclerosis in cell culture: effects of stable prostacyclin analogues, Drug Dev. Res. 9: 189 (1986).Google Scholar
  58. 58.
    H. Jellinek, G. Stock and E. Takacs, Lipofundin arteriosclerosis and iloprost treatment, in: “Prostacyclin and Its Stable Analogue Iloprost”, R.J. Gryglewski and G. Stock, eds., Springer Verlag, Berlin, Heidelberg (1987).Google Scholar
  59. 59.
    R. Bugiardini, M. Galvani, D. Ferrini, C. Gridelli, L. Mari, P. Puddu and S. Lenzi, Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectoris, Am. J. Cardiol. 58: 453 (1986).CrossRefGoogle Scholar
  60. 60.
    R. Bugiardini, M. Galvani, D. Ferrini, C. Gridelli, D. Tollemeto, N. Macri, P. Puddi and S. Lenzi, Myocardial ischemia during intravenous prostacyclin administration: hemodynamic findings and precautionary measures, Am. Heart J. 113: 234 (1987).CrossRefGoogle Scholar
  61. 61.
    F.J. Kiernan, J. Kluger, J.C. Regnier, M. Rutkowski and A. Fieldman, Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction, Br. Heart J. 56: 428 (1986).CrossRefGoogle Scholar
  62. 62.
    P. Henriksson, O. Edhag and A. Wennmalm, Prostacyclin infusion in patients with acute myocardial infarction, Br. Heart J. 53: 173 (1985).CrossRefGoogle Scholar
  63. 63.
    K. Swedberg, P. Held, H. Wadenvik and J. Kutti, Central haemodynamic and antiplatelet effects of iloprost - a new prostacyclin analogue - in acute myocardial infarction in man, Eur. Heart J. 8: 362 (1987).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Fiona M. McDonald
    • 1
  1. 1.Research Laboratories of Schering AG, Berlin (West) and BergkamenBerlin 65 (West)Germany

Personalised recommendations